Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKF-91488 is a small molecule inhibitor of histamine N-methyltransferase (HNMT), the enzyme responsible for the degradation of histamine. By inhibiting HNMT, SKF-91488 prevents the breakdown of histamine, resulting in increased levels of endogenous and exogenous histamine. It acts as a noncompetitive inhibitor with a Ki value around 0.9 µM and has been used primarily in research to study the physiological roles of histamine, including modulation of pain threshold and vascular responses in animal models. It does not exhibit direct agonist activity at histamine receptors[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SKF-91488.